Seaside secures $30 million to fund autism and Fragile X syndrome candidates
This article was originally published in Scrip
Executive Summary
Seaside Therapeutics has raised $30 million to fund the development of its candidates for autism and Fragile X syndrome. The Massachusetts-based firm has secured $66 million in private financing to date.